Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1

Interventions

Bevacizumab 4Zoledronic Acid 3Cisplatin 3Capecitabine 3spartalizumab 2anlotinib 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Metformin 2Letrozole 2Drug Therapy 2vosaroxin 1venetoclax 1tislelizumab 1pembrolizumab 1enzalutamide 1empagliflozin 1atezolizumab 1apatinib 1abiraterone 1XELOX 1Vacuum Curettage 1Tyrosine Kinase Inhibitors 1Tuberculin 1Sorafenib 1Sodium Chloride 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Iodine-123 × Clear all
NCT02418247 2017-01-20

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

National Cancer Center, Korea

Phase 2/3 Unknown
556 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡